{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:12:09Z","timestamp":1791551529949,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10157-023-02372-8","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T08:03:36Z","timestamp":1687853016000},"page":"809-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Hiroshi","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hattanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Mitobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirayasu","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahiro","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Seta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fujimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-5195","authenticated-orcid":false,"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"2372_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317\u201326.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR2","doi-asserted-by":"crossref","unstructured":"Nishio S, Tsuchiya K, Nakatani S, Muto S, Mochizuk0i T, Kawano H, Hanaoka K, Hidaka S, Ichikawa D, Ishikawa E, Uchiyama K, Koshi-Ito E, Hayashi H, Makabe S, Ogata S, Mitobe M, Sekine A, Suwabe T, Kataoka H, Kai H, Kaneko Y, Kurashige M, Seta K, Shimazu K, Hama T, Miura K, Nakanishi K, Horie S, Furuichi K, Okada H, Narita I, Committee of Clinical Practical Guideline for Polycystic Kidney D. A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Clinical and Experimental Nephrology. 2021;25:1292\u2013302.","DOI":"10.1007\/s10157-021-02097-6"},{"key":"2372_CR3","doi-asserted-by":"publisher","first-page":"18056","DOI":"10.1038\/s41598-022-22884-9","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka H, Akagawa H, Yoshida R, Iwasa N, Ushio Y, Akihisa T, Sato M, Manabe S, Makabe S, Kawachi K, Hoshino J, Tsuchiya K, Nitta K, Mochizuki T. Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Sci Rep. 2022;12:18056.","journal-title":"Sci Rep"},{"key":"2372_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka H, Watanabe S, Sato M, Manabe S, Makabe S, Akihisa T, Ushio Y, Iwasa N, Yoshida R, Tsuchiya K, Nitta K, Mochizuki T. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hep Intl. 2021;15:791\u2013803.","journal-title":"Hep Intl"},{"key":"2372_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice Autosomal dominant polycystic kidney disease. The New England J Med. 2008;359:1477\u201385.","journal-title":"The New England J Med"},{"key":"2372_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339\u201342.","journal-title":"Science"},{"key":"2372_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/jcm9010146","volume":"9","author":"H Kataoka","year":"2020","unstructured":"Kataoka H, Fukuoka H, Makabe S, Yoshida R, Teraoka A, Ushio Y, Akihisa T, Manabe S, Sato M, Mitobe M, Tsuchiya K, Nitta K, Mochizuki T. Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 mutations. J Clin Med. 2020;9:146.","journal-title":"J Clin Med"},{"key":"2372_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ekir.2021.12.012","volume":"7","author":"H Kataoka","year":"2022","unstructured":"Kataoka H, Yoshida R, Iwasa N, Sato M, Manabe S, Kawachi K, Makabe S, Akihisa T, Ushio Y, Teraoka A, Tsuchiya K, Nitta K, Mochizuki T. Germline mutations for kidney volume in ADPKD. Kidney Int Rep. 2022;7:537\u201346.","journal-title":"Kidney Int Rep"},{"key":"2372_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","volume":"20","author":"S Horie","year":"2016","unstructured":"Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, Nutahara K, Tsuchiya K, Tsuruya K, Kamura K, Nishio S, Suwabe T, Ubara Y, Ishimura E, Nakanishi K, Furukawa K, Kimura K, Matsuo S. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol. 2016;20:493\u2013509.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S136359","volume":"11","author":"R Barnawi","year":"2018","unstructured":"Barnawi R, Attar R, Alfaer S, Safdar O. Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment. Int J Nephrol Renov Dis. 2018;11:53\u201367.","journal-title":"Int J Nephrol Renov Dis"},{"key":"2372_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0168-8510(02)00199-9","volume":"64","author":"H Nakatani","year":"2003","unstructured":"Nakatani H, Kondo T. Characteristics of a medical care program for specific diseases in Japan in an era of changing cost-sharing. Health Policy. 2003;64:377\u201389.","journal-title":"Health Policy"},{"key":"2372_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2176\/nmc.st.2016-0135","volume":"57","author":"Y Kanatani","year":"2017","unstructured":"Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir. 2017;57:1\u20137.","journal-title":"Neurol Med Chir"},{"issue":"99","key":"2372_CR13","first-page":"S1","volume":"2021","author":"KDIGO","year":"2021","unstructured":"KDIGO. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;2021(99):S1\u201387.","journal-title":"Kidney Int"},{"key":"2372_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41100-017-0097-8","volume":"3","author":"I Masakane","year":"2017","unstructured":"Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K. Annual dialysis data report 2014, JSDT renal data registry (JRDR). Renal Replacement Therapy. 2017;3:18.","journal-title":"Renal Replacement Therapy"},{"key":"2372_CR15","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1038\/s41598-022-07737-9","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka H, Mochizuki T, Ohara M, Tsuruta Y, Iwasa N, Yoshida R, Tsuchiya K, Nitta K, Kimura K, Hosoya T, Investigators F. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study. Sci Rep. 2022;12:3784.","journal-title":"Sci Rep"},{"key":"2372_CR16","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1503\/cmaj.081232","volume":"182","author":"M Harrison","year":"2010","unstructured":"Harrison M, L\u00e9gar\u00e9 F, Graham I, Fervers B. Adapting clinical practice guidelines to local context and assessing barriers to their use. CMAJ. 2010;182:E78\u201384.","journal-title":"CMAJ"},{"key":"2372_CR17","doi-asserted-by":"crossref","unstructured":"Dronkers EAC, Mes S, Wieringa M, van der Schroeff MP, Baatenburg de Jong RJ. Noncompliance to guidelines in head and neck cancer treatment; associated factors for both patient and physician. BMC Cancer. 2015;15:515.","DOI":"10.1186\/s12885-015-1523-3"},{"key":"2372_CR18","doi-asserted-by":"crossref","unstructured":"Bierbaum M, Rapport F, Arnolda G, Tran Y, Nic Giolla Easpaig B, Ludlow K, Braithwaite J. Adherence to clinical practice guidelines (CPGs) for the treatment of cancers in Australia and the factors associated with adherence: a systematic review protocol. BMJ Open. 2021;11:e050912-e.","DOI":"10.1136\/bmjopen-2021-050912"},{"key":"2372_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2011.39.6937","volume":"30","author":"R Chagpar","year":"2012","unstructured":"Chagpar R, Xing Y, Chiang Y-J, Feig B, Chang G, You YN, Cormier J. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30:972\u20139.","journal-title":"J Clin Oncol"},{"key":"2372_CR20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255\u201366.","journal-title":"N Engl J Med"},{"key":"2372_CR21","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"2372_CR22","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, Investigators RT. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"2372_CR23","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","volume":"6","author":"V Torres","year":"2021","unstructured":"Torres V, Gansevoort R, Perrone R, Chapman A, Ouyang J, Lee J, Japes H, Nourbakhsh A, Wang T. Tolvaptan in ADPKD patients with very low kidney function. Kidney International Reports. 2021;6:2171\u20138.","journal-title":"Kidney International Reports"},{"key":"2372_CR24","doi-asserted-by":"crossref","unstructured":"Akihisa T, Manabe S, Kataoka H, Makabe S, Yoshida R, Ushio Y, Watanabe K, Sato M, Tsuchiya K, Mochizuki T, Nitta K. Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease. Kidney 360. 2021;2:1148\u201351.","DOI":"10.34067\/KID.0007342020"},{"key":"2372_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10157-021-02100-0","volume":"25","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance. Clin Exp Nephrol. 2021;25:1231\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s10157-022-02192-2","volume":"26","author":"T Akihisa","year":"2022","unstructured":"Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, Sato M, Tsuchiya K, Mochizuki T, Nitta K. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease. Clin Exp Nephrol. 2022;26:540\u201351.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR27","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.ekir.2021.06.033","volume":"6","author":"S Makabe","year":"2021","unstructured":"Makabe S, Manabe S, Kataoka H, Akihisa T, Yoshida R, Ushio Y, Sato M, Tsuchiya K, Mochizuki T, Nitta K. Urinary aquaporin 2 as a potential indicator predicting tolvaptan response in patients with ADPKD. Kidney Int Rep. 2021;6:2436\u201344.","journal-title":"Kidney Int Rep"},{"key":"2372_CR28","doi-asserted-by":"crossref","unstructured":"Mizuno H, Sekine A, Suwabe T, Ikuma D, Yamanouchi M, Hasegawa E, Sawa N, Ubara Y, Hoshino J. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. PloS One. 2022;17:e0264065-e.","DOI":"10.1371\/journal.pone.0264065"},{"key":"2372_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ekir.2021.11.034","volume":"7","author":"E Higashihara","year":"2022","unstructured":"Higashihara E, Nutahara K, Itoh M, Okegawa T, Tambo M, Yamaguchi T, Nakamura Y, Taguchi S, Kaname S, Yokoyama K, Yoshioka T, Fukuhara H. Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD. Kidney Int Rep. 2022;7:270\u201381.","journal-title":"Kidney Int Rep"},{"key":"2372_CR30","doi-asserted-by":"publisher","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","volume":"11","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Kitayama C, Yanai A, Ishibashi Y. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial. Sci Rep. 2021;11:17666.","journal-title":"Sci Rep"},{"key":"2372_CR31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10157-021-02083-y","volume":"25","author":"S Muto","year":"2021","unstructured":"Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan. Clin Exp Nephrol. 2021;25:1003\u201310.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10157-020-02009-0","volume":"25","author":"S Horie","year":"2021","unstructured":"Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2021;25:467\u201378.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1159\/000509817","volume":"51","author":"A Sekine","year":"2020","unstructured":"Sekine A, Hoshino J, Fujimaru T, Suwabe T, Mizuno H, Kawada M, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Mandai S, Chiga M, Kikuchi H, Ando F, Mori T, Sohara E, Uchida S, Sawa N, Takaichi K, Ubara Y. Genetics may predict effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Am J Nephrol. 2020;51:745\u201351.","journal-title":"Am J Nephrol"},{"key":"2372_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000506118","volume":"10","author":"S Nakatani","year":"2020","unstructured":"Nakatani S, Ishimura E, Machiba Y, Fujimoto K, Uedono H, Tsuda A, Mori K, Emoto M, Inaba M. Long-term effects of high-dose tolvaptan for autosomal dominant polycystic kidney disease patients. Case Rep Nephrol Dialysis. 2020;10:9\u201317.","journal-title":"Case Rep Nephrol Dialysis"},{"key":"2372_CR35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/nep.13196","volume":"23","author":"S Nakatani","year":"2018","unstructured":"Nakatani S, Ishimura E, Machiba Y, Nakatani A, Fujimoto K, Uedono H, Okute Y, Tsuda A, Mori K, Emoto M, Inaba M. Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability. Nephrology. 2018;23:798\u20139.","journal-title":"Nephrology"},{"key":"2372_CR36","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40620-018-0545-8","volume":"31","author":"M Oguro","year":"2018","unstructured":"Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease. J Nephrol. 2018;31:961\u20136.","journal-title":"J Nephrol"},{"key":"2372_CR37","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10157-018-1574-2","volume":"22","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. Clin Exp Nephrol. 2018;22:1213\u201323.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10157-018-1545-7","volume":"22","author":"S Makabe","year":"2018","unstructured":"Makabe S, Mochizuki T, Mitobe M, Aoyama Y, Kataoka H, Tsuchiya K, Nitta K. Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol. 2018;22:1079\u201387.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/DHPS.S142825","volume":"9","author":"S Muto","year":"2017","unstructured":"Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthcare Patient Safety. 2017;9:93\u2013104.","journal-title":"Drug Healthcare Patient Safety"},{"key":"2372_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10157-017-1475-9","volume":"22","author":"S Minami","year":"2018","unstructured":"Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Clin Exp Nephrol. 2018;22:550\u201361.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR41","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","volume":"19","author":"S Muto","year":"2015","unstructured":"Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres V, Horie S. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015;19:867\u201377.","journal-title":"Clin Exp Nephrol"},{"key":"2372_CR42","doi-asserted-by":"crossref","unstructured":"Inoue R, Nishi H, Inoue D, Honda K, Nangaku M. Regional variance of the early use of tolvaptan for autosomal dominant polycystic kidney disease. Kidney 360. 2020;1:740\u20135.","DOI":"10.34067\/KID.0002262020"},{"key":"2372_CR43","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29:2458\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"2372_CR44","doi-asserted-by":"crossref","unstructured":"Jamal A, Babazono A, Li Y, Yoshida S, Fujita T. Multilevel analysis of hemodialysis-associated infection among end-stage renal disease patients: results of a retrospective cohort study utilizing the insurance claim data of Fukuoka Prefecture, Japan. Medicine. 2020;99:e19871-e.","DOI":"10.1097\/MD.0000000000019871"}],"updated-by":[{"DOI":"10.1007\/s10157-023-02426-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02372-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T09:04:33Z","timestamp":1699088673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02372-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2372"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02372-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-023-02426-x","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10157-023-02426-x","URL":"https:\/\/doi.org\/10.1007\/s10157-023-02426-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshio Mochizuki and Hiroshi Kataoka belong to an endowed department sponsored by Otsuka Pharmaceutical Co., Chugai Pharmaceutical Co., Kyowa Kirin Co., and JMS Co. and received honoraria for lectures from Otsuka Pharmaceutical Co. All other authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the institutional ethics review boards of the Japanese Society of Nephrology (authorization number: 70) and Juntendo University (authorization number: 2021016).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for individual consent was waived due to the study's retrospective nature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}